Oncology Biosimilars Market Expanding at 25.0% CAGR During 2017-2025

According to Goldstein Research, global oncology biosimilars market is expected to grow at 25.0% CAGR over the forecast period 2017-2025. The factors such as growth in a number of cancer patients, a rising number of hospitals, and a large number of oncology biosimilars in the pipeline are driving the growth of the Oncology Biosimilars Market. The expansion of the market is positively impacted by expanding the R&D of biomarkers such as in Cancer treatment. The Cancer Biomarker Market is still at the nascent stage and has not yet received approval from FDA, but tremendous R&D will lead to definite results in near future. Further, oncology biosimilars have initiated the trend of ‘precision medicine’ wherein tailored treatment is provided to the individual patient. Hence, the Biosimilar Market is propelling at high growth rate, such that in 2017 European Medicines Agency (EMA) had approved 16 biosimilars. Whereas, European Commission (EC), had approved 19 biosimilars for therapeutic medicines and in total 40 biosimilars across multiple categories till March 2018.

Market Segmentation
On the basis of our in-depth analysis, Global Oncology BiosimilarsMarket can be segmented as follows:
Based on Product Type
•    Monoclonal Antibody
•    Immunomodulators
•    Others

Based on Application
•    Cancer Treatment Drugs
•    Supportive Care Drugs

Based on Distribution Channel
•    Retail Pharmacies
•    Hospital Pharmacies
•    Online Pharmacies

By Region
•    North America Oncology Biosimilars Market Analysis, 2017-2025
•    Europe Oncology Biosimilars Market Analysis, 2017-2025
•    Middle East And Africa Oncology Biosimilars Market Analysis, 2017-2025
•    Latin America Oncology Biosimilars Market Analysis, 2017-2025
•    Asia Pacific Oncology Biosimilars Market Analysis, 2017-2025

“Global Oncology Biosimilars Market Outlook 2025” includes a comprehensive overview of the global oncology biosimilars market. On the basis of our in-depth analysis, the market can be segmented in terms of market segmentation by product type, application, distribution channel and geography.

The Global Oncology Biosimilars Market Report highlights the competitive outlook of major global players that includes business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The comprehensive analysis of the oncology biosimilars market report is drafted as per the clients to help them in assessing their business strategies in a competitive environment.

Key players discussed in the report are:
Amgen, BoehringerIngelheim, Novartis, Biocon, Roche and many more.

Further, Global Oncology Biosimilars Market Report encompasses the key factors driving the growth of the market, opportunities in the market and the factors posing threats & challenges to the market. The oncology biosimilars market outlook also comprises the market dynamics, risk analysis, SWOT analysis, USP analysis, BPS Analysis & market attractiveness. Report further also includes the expert analysis and remarks showcasing the complete overview of the market based on intensive analysis of political, economic, social, technological, environmental & legal factors of each region in the market.